^
Association details:
Biomarker:EGFR R521K
Cancer:Colorectal Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Excerpt:
CXCR1 rs2234671 G>C, CXCR2 rs2230054 T>C, EGFR rs2227983 G>A and VEGFR-2 rs2305948 C>T were significantly associated with RR.
Secondary therapy:
oxaliplatin
DOI:
10.1158/1078-0432.CCR-11-1115